Skip to main content
2025 ASCRS Annual Scientific Meeting Main banner
Final Program


Visit ASCRS U
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Presentation Icons
CME
CME
Invitation/Ticketed Event
Invitation/Ticketed Event
Invited Lectureship
Invited Lectureship
Award Recipient
Award Recipient
Self-Assessment
Self-Assessment
Social
Social
Industry
Industry
Back

Session: Quick Shot: Other Neoplasia and Endoscopy

QS210 - Lactulose versus polyethylene glycol for bowel preparation at colonoscopy: A randomized controlled trial.

Monday, May 12, 2025
10:30 AM – 10:34 AM PT
Location: Room 9, Upper Level

    Quick Shot Presenter(s)

  • Clara E. Valdez Cruz (she/her/hers)

    Resident
    Hospital Civil de Guadalajara
    Guadalajara, Jalisco, Mexico

    All of the relevant financial relationships listed below have been mitigated.
    This individual has no financial relationships with ineligible companies.

    • Author(s)

  • DR

    Diego E. Rodríguez, n/a

    General Surgeon
    Hospital Civil de Guadalajara
    Guadalajara, Jalisco, Mexico

    Disclosure information not submitted.

  • CB

    Carlos A. Bautista Lopez, n/a

    General Surgeon
    Hospital Civil de Guadalajara
    Guadalajara, Jalisco, Mexico

    Disclosure information not submitted.

All of the relevant financial relationships listed below have been mitigated.
Clara E. Valdez Cruz: This individual has no financial relationships with ineligible companies.
Image or Table (Do Not add text here):

Purpose/Background: In this study, we propose to compare the use of a lactulose oral solution (2 l) with a PEG formulation (4 l) for colonoscopy using the following metrics: quality of cleansing colonoscopy results, patient/physician satisfaction, and patient tolerability.

Methods/Interventions: Randomized, controlled, blinded, single-center study performed at the HCFAA, Guadalajara, Jalisco.
Inclusion criteria: patients with age > 18 years, indication for elective colonoscopy/scrutiny/follow-up.
Exclusion criteria: patients with ileostomy, previous colonic resection, intestinal obstruction, DM2 and pregnant women.
All patients underwent a standard clinical and laboratory evaluation including routine blood tests such as hemogram, total leukocyte count, platelet count, coagulation profile, blood glucose (fasting/postprandial), blood urea, serum creatinine and digital rectal examination.
A liquid diet without fiber consumption 24 hours prior to the procedure and 12 hours prior to the bowel preparation will be performed.

Results/Outcomes: A total of 70 patients were evaluated in our study.
In the group of patients administered Lactulose 94.28% mentioned the intestinal preparation as tolerable and only 62.85% in the Polyethylene glycol group, which was statistically significant (p<= 0.005).
11.4% of patients in the Lactulose group presented nausea without vomiting compared to 42.85% in the PEG group, which shows statistical significance (p<= 0.005).
There was no statistical significance in the Boston Intestinal Preparedness Score in both groups (.293-.307).

Conclusion/Discussion: In conclusion, bowel preparation reagents are frequently used in large institutions because of the growing acceptance of colonoscopy examination. Based on safety and effectiveness, our investigation has shown that lactulose has similar intestinal preparation quality as PEG, but it is more palatable and causes less side effects. It is a clinically viable option for bowel preparation in this group of patients.